Symbols

RCEL

AVITA Medical·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RCEL

Avita Medical, Inc.

A leading acute wound treatment company

Industry

Pharmaceutical

Established Date

12/21/1992

Listing Date

06/30/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

226

Fiscal Year Ends

12-31

Website

www.avitamedical.com

Security Type

Common stock

Office address

28159 Avenue Stanford, Suite 220, Valencia, CA 91355

Business

Addressing unmet medical needs in therapeutic skin repair

Introduction

AVITA Medical, Inc., was established in Australia on December 21, 1992. AVITA Medical is a leading acute wound treatment company dedicated to providing transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve the clinical and economic benefits of the entire process of acute wound management. Their technology supports wound bed preparation, eventual closure and rehabilitation through a range of proprietary and complementary products that address critical healing needs such as burns, trauma and surgical repair.

Company Financials

EPS

RCEL has released its 2025 Q4 earnings. EPS was reported at -0.38, versus the expected -0.47, beating expectations. The chart below visualizes how RCEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RCEL has released its 2025 Q4 earnings report, with revenue of 17.61M, reflecting a YoY change of -4.30%, and net profit of -11.62M, showing a YoY change of -0.28%. The Sankey diagram below clearly presents RCEL's revenue sources and cost distribution.